Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have been given an average rating of “Moderate Buy” by the thirteen brokerages that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and nine have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $91.20.

A number of brokerages recently issued reports on HALO. HC Wainwright upped their price target on Halozyme Therapeutics from $95.00 to $115.00 and gave the company a “buy” rating in a report on Friday, August 7th. Leerink Partners raised shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and increased their target price for the company from $83.00 to $110.00 in a research report on Friday, August 7th. Weiss Ratings lowered shares of Halozyme Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday. Wall Street Zen raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Finally, Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st.

Halozyme Therapeutics Trading Up 4.4%

NASDAQ HALO opened at $103.00 on Tuesday. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. Halozyme Therapeutics has a 52 week low of $61.22 and a 52 week high of $104.78. The stock has a market capitalization of $11.69 billion, a PE ratio of 30.75, a price-to-earnings-growth ratio of 0.40 and a beta of 0.85. The firm has a 50 day moving average of $80.30 and a two-hundred day moving average of $72.79.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. The business had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The company’s revenue was up 47.7% on a year-over-year basis. During the same period last year, the business earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, research analysts expect that Halozyme Therapeutics will post 7.77 EPS for the current fiscal year.

Insider Activity

In other news, Director Bernadette Connaughton sold 1,626 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the sale, the director directly owned 40,418 shares of the company’s stock, valued at approximately $4,154,970.40. The trade was a 3.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 1,923 shares of the company’s stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $79.77, for a total value of $153,397.71. Following the completion of the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $61,245,810.60. This trade represents a 0.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 44,103 shares of company stock valued at $3,142,896. Insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

Several large investors have recently modified their holdings of HALO. Arrowstreet Capital Limited Partnership grew its position in shares of Halozyme Therapeutics by 29.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock worth $241,337,000 after acquiring an additional 749,484 shares during the last quarter. Bank of America Corp DE purchased a new stake in Halozyme Therapeutics in the 2nd quarter valued at $214,504,000. William Blair Investment Management LLC purchased a new stake in Halozyme Therapeutics in the 2nd quarter valued at $196,540,000. Dimensional Fund Advisors LP boosted its stake in Halozyme Therapeutics by 1.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company’s stock worth $141,613,000 after purchasing an additional 25,731 shares during the period. Finally, Norges Bank acquired a new stake in Halozyme Therapeutics during the 4th quarter worth $128,201,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.